報價延遲最少15分鐘:2024/11/10 16:57 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.81/-1.71
|
|
企業價值
149.44M
|
| 資產負債 |
|
每股賬面淨值
-1.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
24.75M
|
|
每股收益
1.42
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 16:57 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patientsreceiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. |